Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 8, 2026Cancer Prevention Research

Proteomic analysis of sphingolipid metabolic enzymes with risk of bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) Study

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMichael MarroneEBEvan BagleyKBKenneth R. Butler

Discussion

Loading...

Member takes

Overview

Hypothesis-generating study finds links between sphingolipid enzymes and bladder cancer outcomes in ARIC participants.

Key Points

  • This study aims to explore the relationship between sphingolipid metabolic enzymes and bladder cancer risk and mortality.
  • Analyzed proteomic profiles of plasma from 10,129 individuals in the ARIC study, collected from 1993-1995.
  • Utilized Cox regression for hazard ratios (HRs) and confidence intervals (CIs), adjusting for age, race, sex, and cancer risk factors.
  • Identified 158 incident bladder cancer cases and 47 deaths during a median follow-up of 20 years.
  • SPHK1 enzyme was associated with increased risk of bladder cancer incidence (T3 vs. T1: HR=1.74; 95% CI=1.15-2.63; p-trend=0.008).
  • SPHK1 also linked to bladder cancer mortality (T3 vs. T1: HR=2.39; 95% CI=1.02-5.61; p-trend=0.06).
  • Associations for incidence were weaker in lagged analyses, indicating possible reverse causation; mortality associations remained consistent.

Cite This Study

Marrone et al. (2026) studied this question.

synapsesocial.com/papers/6a4de93fd2ea289ef6283848https://doi.org/10.1158/1940-6207.capr-25-0499
View Full Paper
Ask AI
Bookmark
Share